Eli Lilly has paused attempts to treat monoclonal antibodies against Covid-19 after an independent council of experts raised health concerns, the company said Tuesday.
“We are aware that due to the abundance of caution, the Independent Data Security Monitoring Board ACTIV-3 (DSMB) has recommended a pause in recording,” Eli Lily told Business Insider.
“Lily supports the decision of the independent DSMB to safely ensure the safety of the patients in this study,” he continued.
Dr. Jeremy Faust of Brief19 first announced the break.
Read more: A The new tool in the fight against the coronavirus pandemic has just come close to approval. Here̵
The late-stage study is one of several testing monoclonal antibody treatments based on antibodies from recovered patients for safety and efficacy. Breaks in these studies are not uncommon.
US President Donald Trump was treated with a similar antibody cocktail made by Regeneron while he was hospitalized with the virus earlier this month. On October 7, Lilly applied for urgent approval after sharing early, promising results on how the treatment worked.
Shares of Eli Lilly fell about 2% from previous levels after the announcement.
On Monday, Johnson & Johnson took a break from a three-phase study of its COVID-19 vaccine due to a participant’s “unexplained illness.”